WUXI BIOLOGICS (Germany) Performance
| 1FW1 Stock | EUR 7.00 0.30 4.11% |
The firm maintains a market beta of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, WUXI BIOLOGICS's returns are expected to increase less than the market. However, during the bear market, the loss of holding WUXI BIOLOGICS is expected to be smaller as well. At this point, WUXI BIOLOGICS UNSPADR2 has a negative expected return of -0.29%. Please make sure to check out WUXI BIOLOGICS's treynor ratio, skewness, and the relationship between the total risk alpha and potential upside , to decide if WUXI BIOLOGICS UNSPADR2 performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days WUXI BIOLOGICS UNSPADR2 has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
WUXI |
WUXI BIOLOGICS Relative Risk vs. Return Landscape
If you would invest 865.00 in WUXI BIOLOGICS UNSPADR2 on September 24, 2025 and sell it today you would lose (165.00) from holding WUXI BIOLOGICS UNSPADR2 or give up 19.08% of portfolio value over 90 days. WUXI BIOLOGICS UNSPADR2 is producing return of less than zero assuming 3.0062% volatility of returns over the 90 days investment horizon. Simply put, 26% of all stocks have less volatile historical return distribution than WUXI BIOLOGICS, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
WUXI BIOLOGICS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for WUXI BIOLOGICS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as WUXI BIOLOGICS UNSPADR2, and traders can use it to determine the average amount a WUXI BIOLOGICS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.095
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1FW1 |
Estimated Market Risk
| 3.01 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average WUXI BIOLOGICS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of WUXI BIOLOGICS by adding WUXI BIOLOGICS to a well-diversified portfolio.
WUXI BIOLOGICS Fundamentals Growth
WUXI Stock prices reflect investors' perceptions of the future prospects and financial health of WUXI BIOLOGICS, and WUXI BIOLOGICS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on WUXI Stock performance.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Shares Outstanding | 2.11 B | |||
| Price To Earning | 238.12 X | |||
| Revenue | 13.09 B | |||
| EBITDA | 4.6 B | |||
| Cash And Equivalents | 8.48 B | |||
| Cash Per Share | 4.15 X | |||
| Total Debt | 3.33 B | |||
| Debt To Equity | 0.16 % | |||
| Book Value Per Share | 16.51 X | |||
| Cash Flow From Operations | 1.88 B | |||
| Earnings Per Share | 0.25 X | |||
About WUXI BIOLOGICS Performance
By analyzing WUXI BIOLOGICS's fundamental ratios, stakeholders can gain valuable insights into WUXI BIOLOGICS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if WUXI BIOLOGICS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if WUXI BIOLOGICS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
WuXi Biologics Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the Peoples Republic of China, North America, Europe, and internationally. WuXi Biologics Inc. is a subsidiary of WuXi Biologics Holdings Limited. WUXI BIOLOGICS is traded on Frankfurt Stock Exchange in Germany.Things to note about WUXI BIOLOGICS UNSPADR2 performance evaluation
Checking the ongoing alerts about WUXI BIOLOGICS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for WUXI BIOLOGICS UNSPADR2 help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| WUXI BIOLOGICS generated a negative expected return over the last 90 days | |
| WUXI BIOLOGICS has high historical volatility and very poor performance |
- Analyzing WUXI BIOLOGICS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether WUXI BIOLOGICS's stock is overvalued or undervalued compared to its peers.
- Examining WUXI BIOLOGICS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating WUXI BIOLOGICS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of WUXI BIOLOGICS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of WUXI BIOLOGICS's stock. These opinions can provide insight into WUXI BIOLOGICS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for WUXI Stock analysis
When running WUXI BIOLOGICS's price analysis, check to measure WUXI BIOLOGICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WUXI BIOLOGICS is operating at the current time. Most of WUXI BIOLOGICS's value examination focuses on studying past and present price action to predict the probability of WUXI BIOLOGICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WUXI BIOLOGICS's price. Additionally, you may evaluate how the addition of WUXI BIOLOGICS to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |